Shorted
Opthea logo
OPT
Pharmaceuticals, Biotechnology & Life Sciences

Opthea

Short interest
0.01%
−0.47 pp 30d
as of 13 July 2026
Reported shorts
70.6K
Shares on issue
1.368B

Opthea (OPT) company profile

Profile, insiders and operations

Company

AI-generated research profile of Opthea

Pharmaceuticals
Biotechnology
Eye Disease
Drug Development
Innovation

Opthea is a biopharmaceutical company focused on developing innovative biologics-based therapies for treating vision-threatening eye diseases. The company is pioneering the development of sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, aimed at improving treatment outcomes for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Director trades

20 trades recorded

DateDirectorTypeSharesPriceValue
2026-06-25Unknown Director
buy
---
2026-06-23Jeremy Levin
other
61,390,000$0.003$188,799
2026-06-19KC & LG
buy
---
2026-06-15Katherine Connell
buy
2,000,000$0.015$30,000
2025-12-23KC & LG
buy
---
2025-12-19Katherine Connell
exercise options
41,000,000--
2024-12-17Susan Orr
other
2,000,000--
2024-12-17Quinton Oswald
other
2,000,000--
2024-12-17Julia Haller
other
1,000,000--
2024-12-17Lawrence Gozlan
other
2,000,000--
2024-12-17Anshul Thakral
other
2,000,000--
2024-12-17Sujal Arun Shah
other
2,000,000--
2024-12-17Jeremy Levin
other
2,000,000--
2024-12-17Unknown Director
buy
---
2024-12-17Unknown Director
buy
---
2024-12-17Unknown Director
buy
---
2024-12-17Unknown Director
buy
---
2024-12-17Unknown Director
buy
---
2024-12-17Unknown Director
buy
---
2024-12-17Unknown Director
buy
---

OPT intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required